Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06326684
EARLY_PHASE1

Suvorexant and Alcohol

Sponsor: William Stoops

View on ClinicalTrials.gov

Summary

This research will translate findings from preclinical research and provide the initial clinical evidence that orexin antagonism reduces motivation for alcohol, as well as other alcohol-associated maladaptive behaviors in people with Alcohol Use Disorder. This study will also provide basic science information about the orexinergic mechanisms underlying the pharmacodynamic effects of alcohol in humans. As such, the outcomes will contribute to our understanding of the clinical neurobiology of Alcohol Use Disorder. Overall, the proposed work seeks to expand the scope of current clinical neuroscience research on alcohol addiction by focusing on orexin, which has strong preclinical evidence supporting its critical role in addiction but remains unstudied in humans.

Official title: Influence of Orexin Antagonism on Motivation for Alcohol

Key Details

Gender

All

Age Range

21 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2024-06-07

Completion Date

2027-03-15

Last Updated

2025-12-23

Healthy Volunteers

Yes

Interventions

DRUG

Alcohol

The pharmacodynamic effects of alcohol (0.2 and 0.4 g/kg) will be determined.

DRUG

Placebo

The effects of placebo will be determined.

DRUG

Suvorexant

The effects of suvorexant dose 1 will be determined.

DRUG

Suvorexant

The effects of suvorexant dose 2 will be determined.

Locations (1)

Psychopharmacology of Addiction Laboratory

Lexington, Kentucky, United States